BMS-986527
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 01, 2026
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
(clinicaltrials.gov)
- P1 | N=112 | Not yet recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Monotherapy • New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
1 to 1
Of
1
Go to page
1